Unknown

Dataset Information

0

De novo production of the key branch point benzylisoquinoline alkaloid reticuline in yeast.


ABSTRACT: Microbial biosynthesis for plant-based natural products, such as the benzylisoquinoline alkaloids (BIAs), has the potential to address limitations in plant-based supply of established drugs and make new molecules available for drug discovery. While yeast strains have been engineered to produce a variety of downstream BIAs including the opioids, these strains have relied on feeding an early BIA substrate. We describe the de novo synthesis of the major BIA branch point intermediate reticuline via norcoclaurine in Saccharomyces cerevisiae. Modifications were introduced into yeast central metabolism to increase supply of the BIA precursor tyrosine, allowing us to achieve a 60-fold increase in production of the early benzylisoquinoline scaffold from fed dopamine with no supply of exogenous tyrosine. Yeast strains further engineered to express a mammalian tyrosine hydroxylase, four mammalian tetrahydrobiopterin biosynthesis and recycling enzymes, and a bacterial DOPA decarboxylase produced norcoclaurine de novo. We further increased production of early benzylisoquinoline scaffolds by 160-fold through introducing mutant tyrosine hydroxylase enzymes, an optimized plant norcoclaurine synthase variant, and optimizing culture conditions. Finally, we incorporated five additional plant enzymes--three methyltransferases, a cytochrome P450, and its reductase partner--to achieve de novo production of the key branch point molecule reticuline with a titer of 19.2 ?g/L. These strains and reconstructed pathways will serve as a platform for the biosynthesis of diverse natural and novel BIAs.

SUBMITTER: Trenchard IJ 

PROVIDER: S-EPMC4575844 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

De novo production of the key branch point benzylisoquinoline alkaloid reticuline in yeast.

Trenchard Isis J IJ   Siddiqui Michael S MS   Thodey Kate K   Smolke Christina D CD  

Metabolic engineering 20150710


Microbial biosynthesis for plant-based natural products, such as the benzylisoquinoline alkaloids (BIAs), has the potential to address limitations in plant-based supply of established drugs and make new molecules available for drug discovery. While yeast strains have been engineered to produce a variety of downstream BIAs including the opioids, these strains have relied on feeding an early BIA substrate. We describe the de novo synthesis of the major BIA branch point intermediate reticuline via  ...[more]

Similar Datasets

| S-EPMC4371906 | biostudies-other
| S-EPMC2939906 | biostudies-literature
| S-EPMC10784492 | biostudies-literature
| S-EPMC6730481 | biostudies-literature
| S-EPMC4575454 | biostudies-literature
| S-EPMC5981371 | biostudies-literature
| S-EPMC4003501 | biostudies-literature
| S-EPMC9970956 | biostudies-literature
| S-EPMC2396723 | biostudies-literature
| S-EPMC5831801 | biostudies-other